Womazol Tablet contains Anastrozole 1mg, a non-steroidal aromatase inhibitor used primarily in the management of hormone receptor-positive breast cancer in postmenopausal women. Anastrozole works by selectively inhibiting the aromatase enzyme, which is responsible for the peripheral conversion of androgens to estrogens, thereby reducing circulating estrogen levels. This reduction in estrogen limits the growth of estrogen-dependent breast cancer cells. Womazol is indicated for the adjuvant treatment of early breast cancer, as well as for advanced or metastatic disease in postmenopausal women. It is also utilized in the treatment of breast cancer recurrence following tamoxifen therapy. The recommended dosage is typically one 1mg tablet taken orally once daily, with or without food, as prescribed by a healthcare professional. Patients should be monitored for potential side effects, which may include hot flashes, joint pain, osteoporosis, and fatigue. Womazol is contraindicated in premenopausal women, during pregnancy, and in individuals with hypersensitivity to Anastrozole or any excipients. Regular bone density assessments and liver function tests are advised during prolonged therapy. Womazol should be used under strict medical supervision to optimize therapeutic outcomes and minimize adverse effects.